ZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day.

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,137 calls trading, 1.3x expected, and implied vol increasing almost 2 points ...

Designed to provide broad exposure to the Style Box - Large Cap Growth category of the market, the Direxion NASDAQ-100 Equal Weighted Index Shares (QQQE) is a smart beta exchange traded fund launched ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on ...

Read about how Crispr's robust pipeline for cardiovascular diseases holds blockbuster potential, with top-line results ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

EST Cathie Wood’s ARK Investment bought 58K shares of Crispr Therapeutics (CRSP) todayDon't Miss Our Christmas Offers:Discover the latest ...